Enhancement of Lipoprotein Lipase Activity by Tissue Factor Pathway Inhibitor

Summary

The effect of a basic synthetic peptide, representing the C-terminal region of tissue factor pathway inhibitor (TFPI – Lys²⁵⁴ - Met²⁷⁶), as well as that of the whole protein, on the activity of lipoprotein lipase (LPL) is described. The activity of bovine LPL was measured by chromogenic assay using a water-soluble chromogenic substrate, p-nitrophenyl butyrate. Five and 10 μM concentrations of the peptide increased V_max of bovine LPL by 48.9% and 85.6% respectively as compared with the buffer control without affecting Km. Poly l-lysine, though positively charged did not have any effect, suggesting the importance of the amino acid sequence of the test peptide. On the other hand, 0.25, 0.5 and 1.0 mM n-butyric acid – a product of LPL catalysis in the chromogenic assay, when added to the incubation mixture decreased V_max non competitively by 22.8%, 40.4% and 63% respectively as compared with buffer control, confirming the known product inhibition of LPL. A 100-fold molar excess of n-butyric acid produced inhibition of the LPL reaction as compared with the synthetic peptide which produced potentiation, suggesting a 1:100 stoichiometric interaction of the peptide with n-butyric acid. At a fixed concentration of 0.25 mM substrate, 10 nM full length recombinant TFPI, containing the basic C-terminal domain, increased velocity of LPL reaction by 39.4% as compared with buffer control. The same concentration of two-domain recombinant TFPI (TFPI_1-160) had no effect. It is possible that negatively charged n-butyric acid is sequestered by the positively charged peptide or the basic region of recombinant full length TFPI. Relieving of product inhibition could then be a possible mechanism of the observed potentiation of bovine LPL activity by the basic peptide or full length recombinant TFPI. The 39.4% increase in reaction velocity of LPL catalysis produced by 10 nM full length recombinant TFPI was comparable to 38.9% increase produced by 5 μM of the basic peptide under the same conditions. A further increase of 78.7% was brought about by 10 μM concentration of the same peptide. The reason for about 500-fold increase in the potency of the whole protein as compared with that of the peptide is not clear. It is possible that in its tertiary conformational state, the whole protein is able to sequester product and relieve product inhibition more effectively than the short linear peptide. Rabbit polyclonal antiserum against the basic peptide partially inhibited LPL activity of human post heparin plasma, measured by radioenzymatic assay using triolein substrate. Since post heparin plasma contains full length TFPI, binding of the added antibody to its basic C-terminus and hence the relative unavailability of latter for product sequestration (oleic acid in this case) could explain the observed inhibition of human LPL activity by antibody against the peptide. Thus by enhancing lipase activity, full length TFPI may facilitate hydrolysis of triglyceride and concomitantly lower factor VII coagulant activity as demonstrated earlier, particularly after heparin injection when both TFPI and LPL are released in circulation.

Keywords

TFPI - lipoprotein lipase - p-nitrophenyl butyrate - radioenzymatic assay

• References

• 1 Brunzell JD. In: “Metabolic Basis of Inherited Disease”. Eds. Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw Hill; 1989: 1165-80.
• 2 Camp L, Reina M, Llobera M, Vilaro S, Olivecrona T. Lipoprotein lipase: Cellular origin and functional distribution. Am J Physiol 1990; 258: C673-81.
• 3 Stryer L. In: “Biochemistry”. 4th edition. Publ. New York: WH Freeman and Company; 1995: 603-6.
• 4 Sivaram P, Klein MG, Goldberg IJ. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J Biol Chem 1992; 267: 16517-22.
• 5 Cheng CF, Oosta GM, Bensadonn A, Rosenberg RD. Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem 1981; 256: 12893-8.
• 6 Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Current Opinion Lipidol 1994; 5: 117-25.
• 7 Emmerich J, Beg OU, Peterson J, Previato L, Brunzell JD, Brewer Jr. HB, Santamarina-Fojo S. Human lipoprotein lipase. Analysis of the catalytic triad by site-directed mutagenesis of Ser-132, Asp-156 and His-241. J Biol Chem 1992; 267: 4161-5.
• 8 Bengtsson G, Olivecrona T. Lipoprotein lipase. Mechanism of product inhibition. Eur J Biochem 1980; 106: 557-62.
• 9 Posner I, De Sanctis J. Kinetics of product inhibition and mechanisms of lipoprotein lipase activation by apolipoprotein C-II. Biochemistry 1987; 26: 3711-7.
• 10 Edwards K, Chan RYS, Sawyer WH. Interactions between fatty acids and lipoprotein lipase: Specific binding and complex formation. Biochemistry 1994; 33: 13304-11.
• 11 Wun T-C, Kretzner KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 13: 6001-4.
• 12 Wang C-S. Probing of active site stucture of lipoprotein lipase: Contribution of activation entropy in the catalysis. Biochem Biophys Acta 1994; 1212: 67-72.
• 13 Bengtsson-Olivecrona G, Olivecrona T. Assay of lipoprotein lipase and hepatic lipase. In: “Lipoprotein Analysis. A Practical Approach”. Converse CA, Skinner ER. (eds). The Practical Approach Series. Series eds. Rickwood R, Hames BD. Oxford University Press; 1992: 169-85.
• 14 Hadvary P, Sidler W, Meister W, Vetter W, Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem 1991; 266: 2021-7.
• 15 Quinn DM, Shirai K, Jackson RL, Harmony JAK. Lipoprotein lipase catalysed hydrolysis of water-soluble p-nitrophenyl esters. Inhibition of apolipoprotein C-II. Biochemistry 1982; 21: 6872-9.
• 16 Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis. Platelets 1996; 7: 125-37.
• 17 Aki H, Yamamoto M. Thermodynamic characterization of drug binding to human serum albumin by isothermal titration microcalorimetry. J Pharmaceut Sci 1994; 83: 1712-6.
• 18 Mukherjee M, Dawson G, Sembhi K, Kakkar VV. Triglyceride dependence of factor VII coagulant activity in deep venous thrombosis. Thromb Haemost 1996; 76: 500-1.
• 19 Mukherjee M, Scully MF, Kakkar VV, Phillipou H, Lane DA, Jewitt D. Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action. Thromb Haemost 1997; 77: 675-8.